

IDERA PHARMACEUTICALS, INC.

Form 3

March 12, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â BAKER JULIAN

(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

03/10/2014

3. Issuer Name and Ticker or Trading Symbol

IDERA PHARMACEUTICALS, INC. [IDP]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
☐ Form filed by One Reporting Person
☒ Form filed by More than One Reporting Person

667 MADISON AVENUE, 21ST FLOOR

(Street)

NEW YORK, NY US 10065

(City) (State) (Zip)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

171,548

I

See Footnotes (1) (4)

Common Stock

1,406,423

I

See Footnotes (2) (4)

Common Stock

35,105

I

See Footnotes (3) (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying

4. Conversion

5. Ownership

6. Nature of Indirect Beneficial

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

(Instr. 4)			Derivative Security (Instr. 4)		or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Common Stock Warrant (right to buy)	05/02/2013	05/07/2018	Common Stock	2,250,846	\$ 0.47	I	See Footnotes ⁽¹⁾ (4)
Common Stock Warrant (right to buy)	05/02/2013	05/07/2018	Common Stock	17,626,445	\$ 0.47	I	See Footnotes ⁽²⁾ (4)
Common Stock Warrant (right to buy)	05/02/2013	05/07/2018	Common Stock	439,036	\$ 0.47	I	See Footnotes ⁽³⁾ (4)
Common Stock Warrant (right to buy)	05/02/2013	05/07/2020	Common Stock	1,752,291	\$ 0.01	I	See Footnotes ⁽¹⁾ (4)
Common Stock Warrant (right to buy)	05/02/2013	05/07/2020	Common Stock	13,722,245	\$ 0.01	I	See Footnotes ⁽²⁾ (4)
Common Stock Warrant (right to buy)	05/02/2013	05/07/2020	Common Stock	341,791	\$ 0.01	I	See Footnotes ⁽³⁾ (4)
Common Stock Warrant (right to buy)	09/25/2013	09/25/2020	Common Stock	465,230	\$ 0.01	I	See Footnotes ⁽¹⁾ (4)
Common Stock Warrant (right to buy)	09/25/2013	09/25/2020	Common Stock	3,620,051	\$ 0.01	I	See Footnotes ⁽²⁾ (4)
Common Stock Warrant (right to buy)	09/25/2013	09/25/2020	Common Stock	90,694	\$ 0.01	I	See Footnotes ⁽³⁾ (4)
Common Stock Warrant (right to buy)	02/05/2014	02/10/2021	Common Stock	172,406	\$ 0.01	I	See Footnotes ⁽¹⁾ (4)
Common Stock Warrant (right to buy)	02/05/2014	02/10/2021	Common Stock	1,938,274	\$ 0.01	I	See Footnotes ⁽²⁾ (4)
Common Stock Warrant (right to buy)	02/05/2014	02/10/2021	Common Stock	48,070	\$ 0.01	I	See Footnotes ⁽³⁾ (4)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	Â X	Â	Â	Â
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	Â X	Â	Â	Â
BAKER FELIX	Â X	Â	Â	Â

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

- (4) Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Â

Remarks:

JulianÂ C.Â BakerÂ andÂ Dr.Â KelvinÂ Neu,Â respectivelyÂ aÂ principalÂ andÂ anÂ employeeÂ ofÂ theÂ BakerÂ Bros.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.